WO2008156083A1 - 抗体依存性細胞障害活性を模擬する抗体の結合活性測定法 - Google Patents

抗体依存性細胞障害活性を模擬する抗体の結合活性測定法 Download PDF

Info

Publication number
WO2008156083A1
WO2008156083A1 PCT/JP2008/061049 JP2008061049W WO2008156083A1 WO 2008156083 A1 WO2008156083 A1 WO 2008156083A1 JP 2008061049 W JP2008061049 W JP 2008061049W WO 2008156083 A1 WO2008156083 A1 WO 2008156083A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
activity
dependent cell
mimics
donor
Prior art date
Application number
PCT/JP2008/061049
Other languages
English (en)
French (fr)
Inventor
Masashi Sakita
Takayuki Yoshimori
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Seiyaku Kabushiki Kaisha filed Critical Chugai Seiyaku Kabushiki Kaisha
Priority to US12/452,147 priority Critical patent/US8828666B2/en
Priority to EP08777287.7A priority patent/EP2169404B1/en
Priority to JP2009520487A priority patent/JP5545814B2/ja
Publication of WO2008156083A1 publication Critical patent/WO2008156083A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6408—Fluorescence; Phosphorescence with measurement of decay time, time resolved fluorescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Abstract

　抗原とＦｃレセプターの両者に対する抗体の結合活性を評価できる簡便な方法を提供する。 　蛍光共鳴エネルギー転移が可能なドナー又はアクセプターの一方で標識された抗原又は抗原エピトープと、前記ドナー又はアクセプターの他方で標識されたＦｃレセプター又はその断片と、抗体とを混合する工程、前記ドナーを励起できる波長の光を前記混合物に照射する工程、前記混合物の蛍光量を測定する工程を含む、抗原又は抗原エピトープとＦｃレセプター又はその断片の両者に対する抗体の結合活性を測定する方法。抗体のADCC活性を推定する方法、抗体の品質管理方法、抗体の製造方法、抗体のスクリーニング方法及びこれらの方法に用いるキットも提供される。
PCT/JP2008/061049 2007-06-18 2008-06-17 抗体依存性細胞障害活性を模擬する抗体の結合活性測定法 WO2008156083A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/452,147 US8828666B2 (en) 2007-06-18 2008-06-17 Method for measuring bonding activity of antibody which mimics antibody-dependent cell medicated cytotoxic activity
EP08777287.7A EP2169404B1 (en) 2007-06-18 2008-06-17 METHOD FOR MEASURING BONDING ACTIVITY OF ANTIBODY WITH AN ANTIGEN AND WITH AN Fc RECEPTOR
JP2009520487A JP5545814B2 (ja) 2007-06-18 2008-06-17 抗体依存性細胞障害活性を模擬する抗体の結合活性測定法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007160007 2007-06-18
JP2007-160007 2007-06-18

Publications (1)

Publication Number Publication Date
WO2008156083A1 true WO2008156083A1 (ja) 2008-12-24

Family

ID=40156242

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/061049 WO2008156083A1 (ja) 2007-06-18 2008-06-17 抗体依存性細胞障害活性を模擬する抗体の結合活性測定法

Country Status (4)

Country Link
US (1) US8828666B2 (ja)
EP (1) EP2169404B1 (ja)
JP (1) JP5545814B2 (ja)
WO (1) WO2008156083A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018533725A (ja) * 2015-10-02 2018-11-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 同時結合を測定するための細胞ベースのｆｒｅｔアッセイ法
WO2019131988A1 (en) 2017-12-28 2019-07-04 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
WO2021006328A1 (en) 2019-07-10 2021-01-14 Chugai Seiyaku Kabushiki Kaisha Claudin-6 binding molecules and uses thereof
WO2021010326A1 (ja) 2019-07-12 2021-01-21 中外製薬株式会社 抗変異型ｆｇｆｒ３抗体およびその使用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2980271B1 (fr) 2011-09-16 2013-10-11 Cisbio Bioassays Procede de determination de la glycosylation d'un anticorps
FR2988174B1 (fr) * 2012-03-19 2014-04-25 Cisbio Bioassays Procede de determination de la capacite d'un anticorps a maintenir des cellules a proximite l'une de l'autre
JP6494507B2 (ja) 2012-06-01 2019-04-03 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ グリピカン−３に対する高親和性モノクローナル抗体およびその使用
EP3341738A4 (en) * 2015-08-24 2019-02-27 University of Cincinnati METHOD AND COMPOSITIONS FOR DETECTING FC RECEPTOR BINDING ACTIVITY OF ANTIBODIES
WO2017055404A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for pd1 and tim3
KR102461885B1 (ko) 2017-04-03 2022-11-03 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
KR102346336B1 (ko) 2017-04-05 2022-01-04 에프. 호프만-라 로슈 아게 Pd1 및 lag3에 특이적으로 결합하는 이중특이적 항체
US20210285960A1 (en) * 2018-09-27 2021-09-16 Navrogen Composition and Methods for Measuring Antibody Dynamics
EP4089413A1 (en) * 2021-05-12 2022-11-16 Cisbio Bioassays Method for determining the binding of an antibody to the complement component 1q (c1q)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10319017A (ja) * 1997-05-20 1998-12-04 Toyobo Co Ltd 蛍光エネルギー転移を利用した物質の測定方法およびそのための試薬

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998146A (en) * 1998-07-17 1999-12-07 Wallac Oy Homogeneous luminescence assay method based on energy transfer
GB9901072D0 (en) 1999-01-19 1999-03-10 Imp Cancer Res Tech Methods for detecting changes to a macromolecular component of a cell
AU2002351357A1 (en) * 2001-12-14 2003-06-30 Centocor, Inc. A myeloma cell line useful for manufacturing recombinant proteins in chemically defined media
AU2003236018A1 (en) * 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
WO2006101520A2 (en) 2004-09-20 2006-09-28 University Of Massachusetts Fluorescent proteins and related methods and compounds
JP5315489B2 (ja) * 2005-04-26 2013-10-16 アール クレア アンド カンパニー エフェクター機能が増強されたヒトＩｇＧ抗体を作製する方法
WO2008020823A2 (en) * 2005-05-23 2008-02-21 University Of Hawaii Cooperative reporter systems, components, and methods for analyte detection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10319017A (ja) * 1997-05-20 1998-12-04 Toyobo Co Ltd 蛍光エネルギー転移を利用した物質の測定方法およびそのための試薬

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CASTLES, P. E.: "Human monoclonal antibody stability and : activity at vaginal pH", JOURNAL OF REPRODUCTIVE IMMUNOLOGY, vol. 56, 2001, pages 61 - 76
CLYNES, R A ET AL.: "Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets", NATL. MED., vol. 6, 2000, pages 443, XP002291039, DOI: doi:10.1038/74704
MISHIMA Y.: "Kotai Iyaku up to date - Gan Hen Kotai Iyaku no Hotai Izonsei, Kotai Izonsei Satsusaibo Koka", PHARMA. MED., vol. 25, no. 3, 10 March 2007 (2007-03-10), pages 9 - 13 *
OZAKI S. ET AL.: "M Tampakukessko no Kiso ro Rinsho 8 Kotsuzuishu ni Taisuru Shinki no Kotai Ryoho Tokuni Ko HM1.24 Kotai Ryoho ni Tsuite", KESTUEKI FRONTIER, vol. 12, no. 5, May 2002 (2002-05-01), pages 651 - 659, XP008118295 *
See also references of EP2169404A4
SUMIYA M.: "ADCC no Sokutei Hoho", CLINICAL TESTING, vol. 28, no. 5, May 1984 (1984-05-01), pages 564 - 569 *
SUZUKI T.: "ADCC Kensa", THE JAPANESE JOURNAL OF CLINICAL PATHOLOGY, no. 45, April 1981 (1981-04-01), pages 273 - 282 *
YANO K.: "ADCC no kijo", CLINICAL IMMUNOLOGY, vol. 13, no. 2, February 1981 (1981-02-01), pages 116 - 124 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018533725A (ja) * 2015-10-02 2018-11-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 同時結合を測定するための細胞ベースのｆｒｅｔアッセイ法
WO2019131988A1 (en) 2017-12-28 2019-07-04 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
WO2021006328A1 (en) 2019-07-10 2021-01-14 Chugai Seiyaku Kabushiki Kaisha Claudin-6 binding molecules and uses thereof
WO2021010326A1 (ja) 2019-07-12 2021-01-21 中外製薬株式会社 抗変異型ｆｇｆｒ３抗体およびその使用

Also Published As

Publication number Publication date
EP2169404B1 (en) 2016-01-27
US8828666B2 (en) 2014-09-09
JP5545814B2 (ja) 2014-07-09
JPWO2008156083A1 (ja) 2010-08-26
EP2169404A1 (en) 2010-03-31
EP2169404A4 (en) 2010-08-11
US20100190266A1 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
WO2008156083A1 (ja) 抗体依存性細胞障害活性を模擬する抗体の結合活性測定法
WO2008122793A3 (en) Blood group antibody screening
WO2006069202A3 (en) Compositions comprising anti-igf-i receptor antibodies and methods for obtaining said antibodies
WO2005066867A3 (en) Modulators of cell-surface receptors of the ig-class
PH12017501025A1 (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
WO2005100401A3 (en) Monoclonal antibodies with specificity for fetal erythroid cells
WO2012023053A3 (en) Methods for the generation of multispecific and multivalent antibodies
NZ623706A (en) Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
WO2010027488A3 (en) Monoclonal antibodies
WO2006084092A3 (en) Antibodies to oncostatin m receptor
NO20066052L (no) Anti-CD3 antistoffer og fremgangsmater for anvendelse derav
NZ614857A (en) Bispecific antibodies and methods for production thereof
WO2007120766A3 (en) Erythropoietin receptor agonists
WO2008003103A3 (en) Novel multivalent immunoglobulins
SI1883698T1 (sl) Monoklonska protitelesa in enoverižni protitelesni fragmenti proti celičnemu površinskemu membranskemu antigenu, specifičnemu za prostato
WO2006086208A3 (en) 5-fluoro-uracil immunoassay
NZ591636A (en) Sclerostin binding agents
MX2009009450A (es) Anticuerpos monoclonales para he4 y metodos para su uso.
WO2005090407A8 (en) Human anti-epidermal growth factor receptor antibody
ATE512986T1 (de) Antikörper gegen clostridium difficile-toxine und ihre verwendung
ATE523523T1 (de) Monoklonale anti minichomosome maintenance 2 protein antikörper und verfahren zu deren verwendung beim nachweis einer zervikalen erkrankung
NO20076568L (no) Anti-IL2 antistoffer
WO2008101177A3 (en) Ige antibodies to chimeric or humanized igg therapeutic monoclonal antibodies as a screening test for anaphylaxis
WO2005026730A3 (en) Multiplex binding and activity assays
WO2011064257A3 (de) Monospezifische polypeptidreagenzien

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08777287

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009520487

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008777287

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12452147

Country of ref document: US